Sulaiman, S., Jasim Al-Bayati, M. (2023). Ischemia Modified Albumin in Maternal Serum and Cord Blood in Relation to Preeclampsia Severity and Neonatal Outcome. Alustath, 22(4), 372-378. doi: 10.52573/ipmj.2023.182258
Sarah Hikmat Sulaiman; Maha Mohamed Jasim Al-Bayati. "Ischemia Modified Albumin in Maternal Serum and Cord Blood in Relation to Preeclampsia Severity and Neonatal Outcome". Alustath, 22, 4, 2023, 372-378. doi: 10.52573/ipmj.2023.182258
Sulaiman, S., Jasim Al-Bayati, M. (2023). 'Ischemia Modified Albumin in Maternal Serum and Cord Blood in Relation to Preeclampsia Severity and Neonatal Outcome', Alustath, 22(4), pp. 372-378. doi: 10.52573/ipmj.2023.182258
Sulaiman, S., Jasim Al-Bayati, M. Ischemia Modified Albumin in Maternal Serum and Cord Blood in Relation to Preeclampsia Severity and Neonatal Outcome. Alustath, 2023; 22(4): 372-378. doi: 10.52573/ipmj.2023.182258

Ischemia Modified Albumin in Maternal Serum and Cord Blood in Relation to Preeclampsia Severity and Neonatal Outcome

Iraqi Postgraduate Medical Journal
Volume 22, Issue 4, October 2023, Pages 372-378    PDF (190.16 K)
DOI: 10.52573/ipmj.2023.182258
Authors
Sarah Hikmat Sulaiman* 1; Maha Mohamed Jasim Al-Bayati2
1Health Directorate of Wasit, Al-Aziziya General Hospital, Wasit, Iraq.
2Gynecology and Obstetrics, Retired Professor
Abstract
BACKGROUND:
Preeclampsia is associated with ischemia and increased oxidative stress in the placenta. Ischemia-modified albumin has been widely accepted as a serological biomarker in preeclampsia.
OBJECTIVE:
To evaluate the relationship between maternal serum and cord blood ischemia modified albumin levels with preeclampsia severity and neonatal outcome.
PATIENTS AND METHODS:
This study includes 90 pregnant women who were divided into three groups: Group 1 includes 30 pregnant women with severe preeclampsia. Group 2 includes 30 pregnant women with mild preeclampsia. Group 3 includes 30 normotensive pregnant women with uncomplicated pregnancy considered as control group. The three groups were matched for age and gestational age. Maternal blood sample and neonatal cord blood were collected from all groups and level of ischemia Modified Albumin concentration was measured by kit uses enzyme – linked immune sorbent assay.
RESULTS:  
The mean of maternal serum and cord blood Ischemia modified albumin of group A and Group B were significantly higher than that of group C (P- value =0.001), The study shows significant inverse correlation with neonatal birth weight and level of ischemia modified albumin within the study groups.
CONCLUSION:
Maternal serum and cord blood Ischemia Modified Albumin levels were significantly higher in severe preeclampsia than in mild and uncomplicated normotensive pregnant women, also their levels were inversely correlated with neonatal birth weight.
 
Keywords
Severe preeclampsia; Mild preeclampsia; Ischemia modified albumin
References
  1. Jason J.S. Waugh, Maria C Smith. Hypertensive Disorders. Edamonds DK, Christoph Lees and Tom Bourne. In: Dewhurst s Text book of Obestetrics &gynecology, 9th Black Well publishing. 2018; 7:73-83. 
  2. Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clinical Journal of the American Society of Nephrology.2016;11:1102-13.
  3. Cunningham FG, Leveno JK, Bloom LS, (eds.). Hypertensive disorders. In: Williams s Obestetrics. 25th McGraw-Hill publisher 2018; 40:1566-1667.
  4. Rana S, Lemoine E, Granger J, Karumanchi SA. Preeclampsia: pathophysiology,challenges, and perspectives. Circulation research. 2019;124:1094-112.
  5. Andrei Rebarber. Hypertensive disorders of pregnancy. Errol R. Norwitz, Carolyn M. Zelop, David A. Miller, David L. Keefe. In: Evidence- Based Obestetrics and Gynecology, 1st Wiley Black Well.2019;25:255-64.
 

 

 

  1. Gustaaf Dekker. Hypertension.In: James KD.et al. High Risk Pregnancy Management Options. 4th Saunders, an imprint of Elsevier publishing. 2011;35:599-626.
  2. Bahinipati J, Mohapatra PC. Ischemia modified albumin as a marker of oxidative stress in normal pregnancy. Journal of clinical and diagnostic research: JCDR. 2016;10: BC15.
  3. Rossi A, Bortolotti N, Vescovo S, Romanello I, Forzano L, Londero AP, et al. Ischemia-modified albumin in pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2013;170:348-51.
  4. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000;19:311-15.
  5. Ahmadi R, Rahimi Z, Vaisi-Raygani A, Kiani A, Jalilian N, Rahimi Z. Apolipoprotein E genotypes, lipid peroxidation, and antioxidant status among mild and severe preeclamptic women from Western Iran: protective role of Apolipoprotein ϵ2 Allele in severe Preeclampsia. Hypertension in pregnancy. 2012;31:405-18.
  6. Jakobsen TR, Clausen FB, Rode L, Dziegiel MH, Tabor A. Identifying mild and severe preeclampsia in asymptomatic pregnant women by levels of cell‐free fetal DNA. Transfusion. 2013;53:1956-64.
  7. Üstün Y, Engin-Üstün Y, Öztürk Ö, Alanbay I, Yaman H. Ischemia-modified albumin as an oxidative stress marker in preeclampsia. The Journal of MaternalFetal & Neonatal Medicine. 2011;24:418-21.
  8. Bahinipati J, Mohapatra PC, Pradhan T. Role of maternal serum ischemia modified albumin as a biochemical marker in preeclampsia.
  9. McKenzie KA, Trotman H. A Retrospective Study of Neonatal Outcome in Preeclampsia at the University Hospital of the West Indies: A Resource-limited Setting. Journal of tropical pediatrics. 2019 ;65:78-83.
  10. Weiner E, Feldstein O, Tamayev L, Grinstein E, Barber E, Bar J, Schreiber L, Kovo M. Placental histopathological lesions in correlation with neonatal outcome in preeclampsia with and without severe features. Pregnancy hypertension. 2018;12:6-10.
 

 

  1. D’souza JM, Pai VR, Harish S, Shriyan C, D’souza N. IMA and IMAR in serum and saliva of preeclampsia–a preliminary study. Hypertension in pregnancy. 2014;33:440-48.
Statistics
Article View: 72
PDF Download: 35


Journal Management System. Powered by ejournalplus.com